NO942552L - Humanproteaseinhibitorvarianter av Kunitz-type - Google Patents

Humanproteaseinhibitorvarianter av Kunitz-type

Info

Publication number
NO942552L
NO942552L NO942552A NO942552A NO942552L NO 942552 L NO942552 L NO 942552L NO 942552 A NO942552 A NO 942552A NO 942552 A NO942552 A NO 942552A NO 942552 L NO942552 L NO 942552L
Authority
NO
Norway
Prior art keywords
cys
amino acid
naturally occurring
light
acid residues
Prior art date
Application number
NO942552A
Other languages
English (en)
Norwegian (no)
Other versions
NO942552D0 (no
Inventor
Soeren Erik Bjoern
Kjeld Norris
Fanny Norris
Lars Christian Petersen
Ole Hvilsted Olsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO942552D0 publication Critical patent/NO942552D0/no
Publication of NO942552L publication Critical patent/NO942552L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
NO942552A 1992-01-07 1994-07-06 Humanproteaseinhibitorvarianter av Kunitz-type NO942552L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK9200005 1992-01-07
PCT/DK1993/000002 WO1993014119A1 (en) 1992-01-07 1993-01-07 Human kunitz-type protease inhibitor variants

Publications (2)

Publication Number Publication Date
NO942552D0 NO942552D0 (no) 1994-07-06
NO942552L true NO942552L (no) 1994-09-07

Family

ID=8153776

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942552A NO942552L (no) 1992-01-07 1994-07-06 Humanproteaseinhibitorvarianter av Kunitz-type

Country Status (16)

Country Link
US (1) US5629176A (de)
EP (1) EP0621869B1 (de)
JP (1) JPH07506334A (de)
AT (1) ATE152129T1 (de)
AU (1) AU671611B2 (de)
CA (1) CA2127248A1 (de)
CZ (1) CZ164694A3 (de)
DE (1) DE69310141D1 (de)
FI (1) FI943231A7 (de)
HU (1) HUT70292A (de)
IL (1) IL104327A0 (de)
NO (1) NO942552L (de)
NZ (1) NZ246567A (de)
RU (1) RU94036776A (de)
WO (1) WO1993014119A1 (de)
ZA (1) ZA9398B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
JPH11504938A (ja) * 1995-05-08 1999-05-11 サイオス インク． クニッツ型プロテアーゼ阻害因子
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
PT1587907E (pt) * 2003-01-07 2011-04-08 Dyax Corp Biblioteca de domínios de kunitz
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1981519B1 (de) 2005-12-29 2017-12-27 Dyax Corp. Proteasehemmung
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
EP2379096B1 (de) * 2008-12-19 2019-10-30 Baxalta GmbH Tfpi-inhibitoren und anwendungsverfahren
JP2013516389A (ja) * 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
ES2905545T3 (es) * 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
ES2983470T3 (es) 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
BR112014022435B1 (pt) 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3912638A1 (de) * 1989-04-18 1990-10-31 Bayer Ag Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel
ATE114332T1 (de) * 1989-05-13 1994-12-15 Bayer Ag Proteinaseninhibitoren, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel.
US5278285A (en) * 1990-02-01 1994-01-11 Bayer Aktiengesellschaft Variant of Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology

Also Published As

Publication number Publication date
WO1993014119A1 (en) 1993-07-22
HU9401993D0 (en) 1994-09-28
IL104327A0 (en) 1993-05-13
CA2127248A1 (en) 1993-07-22
ATE152129T1 (de) 1997-05-15
EP0621869B1 (de) 1997-04-23
ZA9398B (en) 1993-08-10
RU94036776A (ru) 1996-09-27
US5629176A (en) 1997-05-13
FI943231L (fi) 1994-07-06
HUT70292A (en) 1995-09-28
DE69310141D1 (de) 1997-05-28
CZ164694A3 (en) 1994-12-15
AU671611B2 (en) 1996-09-05
AU3345793A (en) 1993-08-03
NZ246567A (en) 1996-05-28
NO942552D0 (no) 1994-07-06
EP0621869A1 (de) 1994-11-02
JPH07506334A (ja) 1995-07-13
FI943231A0 (fi) 1994-07-06
FI943231A7 (fi) 1994-07-06

Similar Documents

Publication Publication Date Title
NO942550L (no) Humanproteaseinhibitorvariant av Kunitz-type
NO942552D0 (no) Humanproteaseinhibitorvarianter av Kunitz-type
NO942549L (no) Humanproteaseinhibitorvariant av Kunitz-type
NO942551L (no) Humanproteaseinhibitorvariant av Kunitz-type
RO91186B (ro) Procedeu pentru prepararea unor peptide cu actiune asupra functiei glandei pituitare
NO965411L (no) N-terminalt forlengede proteiner uttrykt i gjær
NO942553D0 (no) Ny humanproteaseinhibitor av Kunitz-type og varianter derav
MX9706974A (es) Endoglucanasas novedosas.
PT2298278E (pt) Prevenção e redução da perda de sangue e resposta inflamatória
DK0466175T3 (da) Porcint CNP-gen og præcursor-protein
AR006517A1 (es) Polipeptido que alcanza un total de alrededor de 30 aminoacidos; sustancia, peptidomimetico y composicion farmaceutica resultantes; usos del polipeptidoy proceso para la sintesis del polipeptido.
ATE375169T1 (de) Modifizierte peptide enthaltende pharmazeutische präparationen
EP0352014A3 (de) Zyklische GRF-Analoge
YU45587B (sh) Postupak za dobijanje grf analoga
Gagnon et al. Primary structure of the A chain of human complement-classical-pathway enzyme C1r. N-terminal sequences and alignment of autolytic fragments and CNBr-cleavage peptides
RU99116976A (ru) Миелопептиды и их терапевтическое использование
DK137085D0 (da) Fremgangsmaade og mellemprodukter til fremstilling af racematfattigepeptider
ATE491724T1 (de) Antiangiogene peptide
ATE283279T1 (de) Therapeutische inhaltsstoffe
SI0789761T1 (en) Human scf, a splice variant thereof, its pharmaceutical use
ES2119746T3 (es) Nuevo peptido fisiologicamente activo y agente regulador del metabolismo del calcio que comprende dicho peptido como ingrediente activo.
TH2482B (th) สารคล้ายคลึง จี อาร์ เอฟ (grf)
FR2787454B1 (fr) Inhibiteur de la topoisomerase ii
TH1778A (th) สารคล้ายคลึง จี อาร์ เอฟ (grf)
TH1653A (th) Grf ของตับอ่อนของคน